Trial results

Semaglutide in Women With Polycystic Ovary Syndrome and Obesity

NCT06896981 on ClinicalTrials.gov · last registry update 2026-10-07

Finished 31 October 2025, after enrolling 31 people. Primary outcome, as filed: Weight. semaglutide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 2 times since then.

Status

COMPLETED

Phase

P2/P3

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Sponsor type

Other

Enrollment

31

Started

2025-01-01

Primary completion

2025-10-31 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Weight

Conditions studied

Polycystic Ovary Syndrome (PCOS) Women · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.